Search Results - "McDonald, Mirna"
-
1
Pharmacokinetics, metabolism and safety of deuterated L‐DOPA (SD‐1077)/carbidopa compared to L‐DOPA/carbidopa following single oral dose administration in healthy subjects
Published in British journal of clinical pharmacology (01-10-2018)“…Aims SD‐1077, a selectively deuterated precursor of dopamine (DA) structurally related to L‐3,4‐dihydroxyphenylalanine (L‐DOPA), is under development for…”
Get full text
Journal Article -
2
Reslizumab as add-on therapy in patients with refractory asthma
Published in BMJ open respiratory research (08-04-2020)“…Approximately 5%–10% of patients with asthma are believed to suffer from severe disease.4 Patients with severe asthma typically require ongoing maintenance…”
Get full text
Journal Article -
3
Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects
Published in Journal of clinical pharmacology (01-09-2014)“…Tafenoquine is being developed for relapse prevention in Plasmodium vivax malaria. This Phase I, single‐blind, randomized, placebo‐ and active‐controlled…”
Get full text
Journal Article -
4
Reslizumab improves FVC and FEF 25%-75% in severe eosinophilic asthma: results from a pooled analysis
Published in Journal of allergy and clinical immunology (01-02-2018)Get full text
Journal Article -
5
Early decreases in blood eosinophil levels with reslizumab
Published in Journal of allergy and clinical immunology (01-04-2019)“…Detailed description of the study designs has been reported previously.5 In brief, eligible patients were aged 12 to 75 years with inadequately controlled…”
Get full text
Journal Article -
6
Fremanezumab Decreases Migraine Symptoms such as Nausea, Vomiting, Photophobia and Phonophobia and Reduces the Need for Acute Medications in the First Week of Treatment in the HFEM Study (P4.111)
Published in Neurology (10-04-2018)“…Abstract only…”
Get full text
Journal Article -
7
Fremanezumab Reduces Headache Pain within the First Week of Beginning Treatment in the Phase 2 Episodic Migraine Study (P4.114)
Published in Neurology (10-04-2018)“…Abstract only…”
Get full text
Journal Article -
8
Reslizumab improves FVC and FEF25%-75% in severe eosinophilic asthma: results from a pooled analysis
Published in Journal of allergy and clinical immunology (01-02-2018)“…Rationale IV reslizumab (RES), a humanized anti-interleukin-5 monoclonal antibody, demonstrated significant improvement in FEV1 at 52 weeks in patients aged…”
Get full text
Journal Article -
9
Baseline Characteristics Associated with Quartiles of Reslizumab Effect: Pooled Analysis Of Two Phase 3 Studies
Published in Journal of allergy and clinical immunology (01-02-2018)“…Rationale IV reslizumab (RES), a humanized anti-interleukin-5 monoclonal antibody, significantly reduced risk of asthma exacerbations and improved asthma…”
Get full text
Journal Article -
10
Improvements In Individual Asthma Control Questionnaire (ACQ-5) Questions With Reslizumab In Patients With Inadequately Controlled Asthma and Elevated Blood Eosinophils: Pooled Analysis of Two Phase 3 Trials
Published in Journal of allergy and clinical immunology (01-02-2018)“…Results Compared to PBO (n=475), RES (n=477) resulted in improvement in Q1 (nighttime awakenings [NA]) by -0.3, Q2 (morning symptoms [MS]) by -0.5, Q3…”
Get full text
Journal Article -
11
Association Between Asthma Exacerbations and Lung Function With Reslizumab Treatment In Patients With Uncontrolled Eosinophilic Asthma: Pooled Analysis of Two Phase 3 Trials
Published in Journal of allergy and clinical immunology (01-02-2018)“…Rationale Reslizumab (RES), a humanized anti-interleukin-5 monoclonal antibody, significantly reduced the risk of clinical asthma exacerbation (CAE) in…”
Get full text
Journal Article -
12
The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post‐Hoc Analyses on the First 3 Weeks of Treatment
Published in Headache (01-03-2019)“…Background Migraine has a substantial impact on daily living, affecting productivity and quality of life for patients and their families. Patients frequently…”
Get full text
Journal Article -
13
Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials
Published in Cephalalgia (01-01-2019)“…In phase 2 and 3 studies, fremanezumab, a monoclonal CGRP antibody, was an effective preventive treatment for high-frequency episodic migraine (HFEM) and…”
Get more information
Journal Article -
14
Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials
Published in The journal of allergy and clinical immunology in practice (Cambridge, MA) (01-02-2020)“…Intravenous reslizumab, a monoclonal IL-5 antibody, is approved for treating severe asthma with eosinophilia. Limited structured information is available on…”
Get full text
Journal Article -
15
Efficacy of Reslizumab in Asthma Patients with Aspirin Sensitivity and Elevated Blood Eosinophils
Published in Journal of allergy and clinical immunology (01-02-2017)“…Conclusions Patients with inadequately controlled asthma, elevated blood eosinophils, and ASA sensitivity (±CRSwNP) received significant therapeutic benefit,…”
Get full text
Journal Article -
16
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps
Published in The journal of allergy and clinical immunology in practice (Cambridge, MA) (01-02-2019)“…An estimated 7% of patients with asthma have chronic rhinosinusitis with nasal polyps (CRSwNP), and more than 80% have at least some radiographic evidence of…”
Get full text
Journal Article